SG10201705673QA - Polymorphs Of 2-(4-(2-(1-Isopropyl-3-Methyl-1H-1,2,4-Triazol-5-Yl)-5,6-Dihydrobenzo[F]Imidazo[1,2-D][1,4] Oxazepin-9-Yl)-1H-Pyrazol-1-Yl)-2-Methylpropanamide, Methods Of Production, And Pharmaceutical Uses Thereof - Google Patents
Polymorphs Of 2-(4-(2-(1-Isopropyl-3-Methyl-1H-1,2,4-Triazol-5-Yl)-5,6-Dihydrobenzo[F]Imidazo[1,2-D][1,4] Oxazepin-9-Yl)-1H-Pyrazol-1-Yl)-2-Methylpropanamide, Methods Of Production, And Pharmaceutical Uses ThereofInfo
- Publication number
- SG10201705673QA SG10201705673QA SG10201705673QA SG10201705673QA SG10201705673QA SG 10201705673Q A SG10201705673Q A SG 10201705673QA SG 10201705673Q A SG10201705673Q A SG 10201705673QA SG 10201705673Q A SG10201705673Q A SG 10201705673QA SG 10201705673Q A SG10201705673Q A SG 10201705673QA
- Authority
- SG
- Singapore
- Prior art keywords
- oxazepin
- methylpropanamide
- dihydrobenzo
- polymorphs
- imidazo
- Prior art date
Links
- BEUQXVWXFDOSAQ-UHFFFAOYSA-N 2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide Chemical compound CC(C)N1N=C(C)N=C1C1=CN(CCOC=2C3=CC=C(C=2)C2=CN(N=C2)C(C)(C)C(N)=O)C3=N1 BEUQXVWXFDOSAQ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361916657P | 2013-12-16 | 2013-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201705673QA true SG10201705673QA (en) | 2017-08-30 |
Family
ID=52023532
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201604903VA SG11201604903VA (en) | 2013-12-16 | 2014-12-15 | Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1h-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1h-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereof |
SG10201705669QA SG10201705669QA (en) | 2013-12-16 | 2014-12-15 | Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1h-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1h-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereof |
SG10201705673QA SG10201705673QA (en) | 2013-12-16 | 2014-12-15 | Polymorphs Of 2-(4-(2-(1-Isopropyl-3-Methyl-1H-1,2,4-Triazol-5-Yl)-5,6-Dihydrobenzo[F]Imidazo[1,2-D][1,4] Oxazepin-9-Yl)-1H-Pyrazol-1-Yl)-2-Methylpropanamide, Methods Of Production, And Pharmaceutical Uses Thereof |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201604903VA SG11201604903VA (en) | 2013-12-16 | 2014-12-15 | Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1h-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1h-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereof |
SG10201705669QA SG10201705669QA (en) | 2013-12-16 | 2014-12-15 | Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1h-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1h-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereof |
Country Status (17)
Country | Link |
---|---|
US (2) | US9266903B2 (fr) |
EP (1) | EP3083640A1 (fr) |
JP (2) | JP6302089B2 (fr) |
KR (2) | KR101902664B1 (fr) |
CN (2) | CN105829323B (fr) |
AR (1) | AR098762A1 (fr) |
AU (3) | AU2014365079B2 (fr) |
BR (1) | BR112016009665A8 (fr) |
CA (1) | CA2927125A1 (fr) |
HK (1) | HK1223101A1 (fr) |
IL (2) | IL244915A0 (fr) |
MX (1) | MX356804B (fr) |
RU (2) | RU2658009C2 (fr) |
SG (3) | SG11201604903VA (fr) |
TW (2) | TWI638818B (fr) |
WO (1) | WO2015091305A1 (fr) |
ZA (1) | ZA201602534B (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2017016346A (es) * | 2015-06-29 | 2018-05-02 | Hoffmann La Roche | Metodos de tratamiento con taselisib. |
IL256299B2 (en) * | 2015-06-30 | 2023-11-01 | Genentech Inc | Immediate-release tablets containing a drug and processes for creating the tablets |
CN110650963B (zh) | 2017-04-28 | 2022-09-27 | 豪夫迈·罗氏有限公司 | Gdc-0077的多晶型物和固体形式及其制备方法 |
JP2020535212A (ja) * | 2017-09-27 | 2020-12-03 | フェドラ・ファーマシューティカルズ・インコーポレイテッドFedora Pharmaceuticals Inc. | ジアザビシクロオクタン誘導体の結晶型及びその生産プロセス |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8242104B2 (en) | 2009-09-28 | 2012-08-14 | F. Hoffman-La Roche Ag | Benzoxazepin P13K inhibitor compounds and methods of use |
SG10201706196XA (en) * | 2012-06-08 | 2017-08-30 | Hoffmann La Roche | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
CA2948765A1 (fr) * | 2013-03-13 | 2014-09-18 | F. Hoffmann-La Roche Ag | Derives de (4-bromo-2-fluorophenyl)-1h-imidazoyl intermediaires destinesa un processus de synthese de composes de benzoxazepine |
-
2014
- 2014-12-15 JP JP2016558275A patent/JP6302089B2/ja active Active
- 2014-12-15 CN CN201480068672.4A patent/CN105829323B/zh active Active
- 2014-12-15 US US14/570,019 patent/US9266903B2/en active Active
- 2014-12-15 AU AU2014365079A patent/AU2014365079B2/en not_active Ceased
- 2014-12-15 MX MX2016007581A patent/MX356804B/es active IP Right Grant
- 2014-12-15 AR ARP140104667A patent/AR098762A1/es unknown
- 2014-12-15 BR BR112016009665A patent/BR112016009665A8/pt not_active Application Discontinuation
- 2014-12-15 CA CA2927125A patent/CA2927125A1/fr not_active Abandoned
- 2014-12-15 RU RU2016127039A patent/RU2658009C2/ru not_active IP Right Cessation
- 2014-12-15 TW TW103143724A patent/TWI638818B/zh not_active IP Right Cessation
- 2014-12-15 TW TW105143616A patent/TW201731852A/zh unknown
- 2014-12-15 KR KR1020167015862A patent/KR101902664B1/ko active IP Right Grant
- 2014-12-15 WO PCT/EP2014/077666 patent/WO2015091305A1/fr active Application Filing
- 2014-12-15 CN CN201811256901.1A patent/CN109293674A/zh active Pending
- 2014-12-15 KR KR1020187023324A patent/KR20180093138A/ko not_active Application Discontinuation
- 2014-12-15 RU RU2018119749A patent/RU2018119749A/ru unknown
- 2014-12-15 SG SG11201604903VA patent/SG11201604903VA/en unknown
- 2014-12-15 EP EP14811921.7A patent/EP3083640A1/fr not_active Withdrawn
- 2014-12-15 SG SG10201705669QA patent/SG10201705669QA/en unknown
- 2014-12-15 SG SG10201705673QA patent/SG10201705673QA/en unknown
-
2016
- 2016-01-08 US US14/991,658 patent/US9481690B2/en active Active
- 2016-04-05 IL IL244915A patent/IL244915A0/en unknown
- 2016-04-14 ZA ZA201602534A patent/ZA201602534B/en unknown
- 2016-09-29 HK HK16111381.6A patent/HK1223101A1/zh unknown
- 2016-11-14 IL IL248965A patent/IL248965A0/en unknown
-
2017
- 2017-06-06 AU AU2017203817A patent/AU2017203817B2/en not_active Ceased
- 2017-06-06 AU AU2017203819A patent/AU2017203819B2/en not_active Ceased
- 2017-12-20 JP JP2017244553A patent/JP2018080179A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1198476A1 (zh) | 咪唑啉類衍生物、其製備方法及其在醫藥上的應用 | |
SG11201405221PA (en) | Catheter die and method of fabricating the same | |
HK1248214A1 (zh) | 新噻吩並嘧啶衍生物、其製備方法及其治療用途 | |
EP3041569A4 (fr) | Détection de zones cardiaques souffrant d'un déficit de régulation | |
IL267464A (en) | Polymorphs and solid forms of (s)-2-((2-((s-4-(difluoromethyl)-2-oxoxolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][ 1,4]oxazepin-9-yl)amino)propanamide and methods of production | |
IL248965A0 (en) | Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1h-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4]oxazapine-9-yl)-2-methylpropanamide, preparation methods and their pharmaceutical uses | |
SG11201405270UA (en) | Method for the production of polyols and uses thereof | |
IL281087A (en) | Process for preparing (S)-2-((2-((S)-4-(difluoromethyl)-2-oxoxazolidine-3-YL)-6,5-dihydrobenzo[F]imidazo[2,1-D][4 , 1]oxazapine-9-YL)amino)propanamide | |
HK1201060A1 (zh) | -二甲基苯基 -丙醛的製備方法 | |
EP3004085A4 (fr) | Dérivés d'imidazole et leurs procédés d'utilisation pour améliorer la pharmacocinétique d'un médicament | |
EP3068391A4 (fr) | Dérivés de triazole et d'imidazole à liaison aryle et leurs procédés d'utilisation pour améliorer la pharmacocinétique d'un médicament | |
EP2842940A4 (fr) | Composés dérivés de sulforaphane, procédé d'obtention et son utilisation médicale, alimentaire et cosmétique | |
HK1212968A1 (zh) | 氨基環丁烷衍生物、其製備方法及其用作藥物的用途 | |
ZA201407558B (en) | Itq-49 material, method for the production thereof and use of same | |
HK1210617A1 (en) | Process for the preparation of heterocyclic ester derivatives | |
HK1208454A1 (zh) | 治療細菌性疾病的嘧啶衍生物 | |
IL236480B (en) | A process for the preparation of n-oxides of 5-(1-alkylthio)alkyl-pyridine substituted in position 2 | |
AP3759A (en) | Method for preparing phenyloxymethyl-nitro-imidazole derivatives and use of the same | |
EP2964659A4 (fr) | Procédé pour la préparation de déférasirox | |
ZA201408723B (en) | Emulsion for pharmaceutical use and method for the production thereof | |
AU2012902577A0 (en) | Body Measuring Method and Garment Production Method and System | |
ZA201201061B (en) | Process for the preparation of bromopyrimidine derivative |